New York Pharma Forum - Dealmaking 2017
New York Pharma Forum January 2017 Double ProgramProgram 1
TOPIC: AMED in America: Creating New Opportunities for US-Japan Collaboration
The Japan Agency for Medical Research and Development (AMED) recently opened a U.S. office in Washington D.C., headed by Takiko Sano. The Japanese government established AMED in 2015 to accelerate R&D to bring innovative medicines to market. AMED is aggressively working with global partners to commercialize the research. For the first program, Ms. Sano will introduce AMED (often compared to the U.S. NIH), speak about the mission for its U.S. office, access to and commercialization of Japanese IP, and the opportunities they bring to the table for US biopharma companies.
Takiko Sano, Head of US Office, Japan Agency for Medical Research and Development(AMED)
TOPIC: Dealmaking 2017
The second program will feature speakers discussing dealmaking trends and the new and unique opportunities for biopharma companies in 2017 related to tech transfers / IP acquisition. Given the research happening at top universities across the country, tech transfers are an important source of IP for companies, providing numerous commercialization opportunities.
Abram Goldfinger, Executive Director, Office of International Liaison, New York University
Samuel Waxman, Partner, Paul Hastings LLP
Event Location:The Nippon Club145 West 57th StreetNew York, NY
*Additional Speakers TBA